Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: A 16-week open-label extension phase and both phases of a randomized controlled trial

Journal of Clinical Psychiatry

Volumn 72, Issue 3, 2011, Pages 326-330

  Tchoukhine, Evgueni ^a   Takala, Pirjo ^b   Hakko, Helinä ^c   Raidma, Mirjam ^d   Putkonen, Hanna ^b   Räsänen, Pirkko ^d,e   Terevnikov, Viacheslav ^d   Stenberg, Jan Henry ^a   Eronen, Markku ^b   Joffe, Grigori ^d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b VANHA VAASA HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d Kellokoski Hospital   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ARTICLE; BEHAVIOR MODIFICATION; BODY WEIGHT; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; MALE; METABOLIC PARAMETERS; OBESITY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; ANTIPYRETICS; BENZODIAZEPINES; CHOLESTEROL; CHOLESTEROL, LDL; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; MALE; OBESITY; SCHIZOPHRENIA; SEX FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 79953033919     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05283yel     Document Type: Article

References (20)

1. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64(7):701-723. doi:10.2165/03495-20464070-03 PubMed (Pubitemid 38471372)
2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19(suppl 1):1-93. doi:10.2165/023210-2051901-01 PubMed (Pubitemid 40677047)
3. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62(suppl 27):15-26. PubMed
4. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13. PubMed
5. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57. doi:10.1016/S0920-964(02)0498-X PubMed (Pubitemid 38030344)
6. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68(suppl 1):20-27. PubMed
7. Shaw KA, O'Rourke P, Del Mar C, et al. Psychological interventions for overweight or obesity. Cochrane Database Syst Rev. 2005;2:CD003818. PubMed
8. Padwal RS, Rucker D, Li SK, et al. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003; 4(4): CD004094. doi:10.102/14651858.CD04094.pub2 PubMed
9. Pagotto U, Vanuzzo D, Vicennati V, et al. Pharmacological therapy of obesity [in Italian]. G Ital Cardiol (Rome). 2008;9(suppl 1):83S-93S. PubMed
10. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr Bull. 2007;33(3):654-656. doi:10.1093/schbul/sbm02 PubMed (Pubitemid 47343724)
11. Lucas KH, Kaplan-Machlis B. Orlistat: a novel weight loss therapy. Ann Pharmacother. 2001;35(3):314-328. doi:10.1345/aph.19412 PubMed (Pubitemid 32203695)
12. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapinetreated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5): 706-711. doi:10.408/JCP.v69n0503 PubMed (Pubitemid 351838679)
13. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161. doi:10.237/diacare.27.1.15 PubMed (Pubitemid 38196725)
14. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr. 2004;80(6):1461-1468. PubMed
15. Bautista-Castaño I, Molina-Cabrillana J, Montoya-Alonso JA, et al. Variables predictive of adherence to diet and physical activity recommendations in the treatment of obesity and overweight, in a group of Spanish subjects. Int J Obes Relat Metab Disord. 2004;28(5):697-705. doi:10.1038/sj.ijo.0802602 PubMed (Pubitemid 38580979)
16. Friedman KE, Applegate KL, Grant J. Who is adherent with preoperative psychological treatment recommendations among weight loss surgery candidates? Surg Obes Relat Dis. 2007;3(3):376-382. doi:10.1016/j.soard.207.01.08 PubMed
17. Reynolds TM, Mardani A, Twomey PJ, et al. Targeted versus global approaches to the management of hypercholesterolaemia. J R Soc Promot Health. 2008;128(5):248-254. doi:10.17/14642408092797 PubMed
18. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22(3):244-251. doi:10.1097/04714-202060-03 PubMed (Pubitemid 34546838)
19. Hilger E, Quiner S, Ginzel I, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol. 2002;22(1):68-70. doi:10.1097/04714-202020-01 PubMed (Pubitemid 34101295)
20. Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry. 2008;41(1):17-23. doi:10.105/s-207-92148 PubMed (Pubitemid 351195888)